Updates are available Correction dated 2020-10-27

Article History

First Online: 27 October 2020

Change Date: 27 October 2020

Change Type: Correction

Change Details: The article Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

Compliance with Ethical Standards

:

: R. K. Ramanathan is currently employed by Merck and received research funding from Bayer for the conduct of the study. D.D. Von Hoff is employed as a consultant at McKesson; reports stock and ownership at Anthem, Inc., CerRx, Medtronic, Stromatis Pharma, SynDevRx, Systems Oncology, and UnitedHealthcare; has participated in a consulting or advisory role for Aadi, Actinium Pharmaceuticals, Adicet Bio, Aeglea BioTherapeutics, Agenus, AiMed Bio, Alpha Cancer Technologies, Amunix, APEIRON, Aptose Biosciences, Arvinas, Athenex, Bellicum Pharmaceuticals, BioLineRx, BioSpecifics Technologies, BioXCel Therapeutics, Boston Scientific, Bryologyx, CanBas, Celgene, Codiak Biosciences, Corcept Therapeutics, CORRONA, CV6 Therapeutics, CytomX Therapeutics, Decoy Biosystems, DNAtrix, EMD Serono, Erimos Pharmaceuticals, Esperance Pharmaceuticals, Evelo Biosciences, Fate Therapeutics, FibroGen, Five Prime Therapeutics, Fujifilm, Geistlich Pharma, Genzada Pharmaceuticals, Gimbal, GiraFpharma, Globe Life Sciences, Helix BioPharma, Hills Pharma, Histogen, Horizon Discovery, HUYA Bioscience International, Imaging Endpoints, Immodulon Therapeutics, Immunophotonics, Innokeys, Intezyne Technologies, Ipsen, Jounce Therapeutics, Kalos Therapeutics, Kelun-Klus Pharma, Kura, L.E.A.F. Pharmaceuticals, Lixte Biotechnology, Medical Prognosis Institute, Novita Pharmaceuticals, Novocure, NuCana BioMed, Oncology Venture, Oncolyze, Pfizer, Phosplatin Therapeutics, Radimmune, RefleXion Medical, RenovoRx, Riptide Bioscience, Samumed, Samus Therapeutics, Senhwa Biosciences, Sirnaomics, Sobi, SOTIO, Strategia Therapeutics, Sun Biopharma, Synergene, TD2, Tolero Pharmaceuticals, TP Therapeutics, TransMed, Trovagene, Verily, Vicus Therapeutics, and 2X Oncology; and has received research funding from AbbVie, Aduro Biotech, Agios, ArQule, Baxalta, Celgene, Cleave Biosciences, CytRx Corporation, Daiichi Sankyo, Deciphera, Endocyte, ESSA, Exelixis, Five Prime Therapeutics, Genentech, Gilead Sciences, Halozyme, Incyte, Lilly, Merck, Merrimack, Minneamrita Therapeutics, Mirna Therapeutics, Pfizer, Pharmacyclics, Phoenix Biotech, Plexxikon, Proderm IQ, Samumed, Strategia, Trovagene, Verastem, and 3-V Biosciences. G. Blumenschein Jr has received grants from Adaptimmune, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Exelixis, Genentech, GlaxoSmithKline, Immatics, Immunocore, Incyte, Kite Pharma, MacroGenics, MedImmune, Merck, Novartis, Roche, Tmunity, Torque, and Xcovery; and has received personal fees from AbbVie, Adicet, Amgen, ARIAD, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Clovis, Genentech, Johnson & Johnson, Maverick Therapeutics, MedImmune, Merck, Novartis, Roche, Virogin Biotech, and Xcovery. I. Genvresse is employed by Bayer AG. C. Granvil is employed by Bayer HealthCare Pharmaceuticals, Inc. A. Skubala is employed by Chrestos Concept GmbH & Co. KG and acts as a consultant to Bayer. C. Peña is employed by and owns stock at Bayer HealthCare Pharmaceuticals, Inc., and is a co-inventor on Bayer patents related to one of the investigational drugs used in the present study. K. Mross has received grants and support for travel from Bayer AG. F. Eskens, D. Richards, and S. Reschke report no conflicts of interest.

: We thank Jack Adams, MSc, of Complete HealthVizion for providing medical writing assistance with the manuscript, based on detailed discussion and feedback from all authors. This assistance was funded by Bayer AG.

: The study was compliant with the Declaration of Helsinki and Good Clinical Practice, and was approved by the appropriate ethics committees. All patients provided written, informed consent.